LXEO

NASDAQ open

Lexeo Therapeutics

3.01 USD
▲+0.06+2.03%
盘后 2.91 0.00%
2026-11-20
市值
$245.04M
市盈率
—
EPS
-1.27
股息率
—
52 周区间
2.55 – 10.99
成交量
1.16M
Beta
1.65
目标价
25.11
52W 低 2.5552W 高 10.99
价格走势

公司简介

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...